No Relation between Body Temperature and Arterial Recanalization at Three Days in Patients with Acute Ischaemic Stroke

Marjolein Geurts1,*, H. Bart van der Worp1, Alexander D. Horsch2, L. Jaap Kappelle1, Geert J. Biessels1, Birgitta K. Velthuis2, DUST investigators¶

1Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands, 2Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands

¶Names of the DUST investigators are provided in the Acknowledgments

* m.geurts-2@umcutrecht.nl

Abstract

Background
Recanalization of an occluded intracranial artery is influenced by temperature-dependent enzymes, including alteplase. We assessed the relation between body temperature on admission and recanalization.

Methods
We included 278 patients with acute ischaemic stroke within nine hours after symptom onset, who had an intracranial arterial occlusion on admission CT angiography, in 13 participating centres. We calculated the relation per every 0.1°Celsius increase in admission body temperature and recanalization at three days.

Results
Recanalization occurred in 80% of occluded arteries. There was no relation between body temperature and recanalization at three days after adjustments for age, NIHSS score on admission and treatment with alteplase (adjusted odds ratio per 0.1°Celsius, 0.99; 95% confidence interval, 0.94–1.05; p = 0.70). Results for patients treated or not treated with alteplase were essentially the same.

Conclusions
Our findings suggest that in patients with acute ischaemic stroke there is no relation between body temperature on admission and recanalization of an occluded intracranial artery three days later, irrespective of treatment with alteplase.
Introduction

In patients with acute ischaemic stroke, recanalization of the occluded cerebral artery is strongly associated with improved functional outcome [1]. Spontaneous recanalization is influenced by temperature-dependent enzymes [2], and the in vitro activity of alteplase reduces with lower temperatures [3]. Whether body temperature also affects in vivo recanalization with or without alteplase is uncertain. This might be important, because guidelines recommend the use of antipyretics in stroke patients with fever [4, 5] and two phase III trials of therapeutic hypothermia for ischaemic stroke are in progress [6, 7]. We assessed the relation between body temperature and recanalization in patients with acute ischaemic stroke, treated with or without intravenous alteplase.

Methods

This is a substudy of the Dutch acute Stroke study (DUST), a prospective multi-centre cohort study including adult patients with acute ischemic stroke within nine hours after symptom onset between May 2009 and July 2013. The design, eligibility criteria, and neuroimaging protocol have been reported previously [8]. All patients underwent non-contrast CT, CT perfusion, and CT angiography (CTA) within 9 hours after symptom onset. In this substudy, we included patients with visible intracranial arterial occlusion on admission CTA, and follow-up vascular imaging at 3 (±2) days. Patients who received intra-arterial treatment were excluded. Body temperature was recorded on admission.

Stroke severity at admission was assessed with the National Institutes of Health Stroke Scale (NIHSS). Stroke subtype was recorded according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification. Recanalization was assessed on follow-up vascular imaging and classified as no recanalization on the one hand, or partial or complete recanalization on the other. All scans were centrally evaluated by one of three experienced observers, who were blinded for the clinical data except for the side of symptoms. Poor functional outcome was defined as a modified Rankin Scale (mRS) score ≥3 at 90 days.

Temperature data were retrospectively collected from patients’ charts by one investigator, blinded for outcome measures. Body temperature on admission was defined as first recorded body temperature within twelve hours after admission, measured either tympanic or rectal. The medical ethics committee of the University Medical Center Utrecht approved the DUST study, and written informed consent was obtained from each patient or a legal representative.

Statistical analysis

The relation per 0.1°Celsius increase in admission body temperature and recanalization or functional outcome was calculated by means of logistic regression with a generalized estimating equations model, and expressed as an odds ratio (OR) with a corresponding 95% confidence interval (CI). We adjusted for age, NIHSS score on admission and treatment with alteplase.

Pre-defined subgroup analyses were performed with regard to treatment with alteplase and etiology of stroke. In a separate analysis patients were stratified according to the time of the second CT angiography.

Finally, we performed two additional analyses assuming that either none or all of the patients excluded because of no follow up imaging had recanalization.

Results

Of the 1393 patients in DUST, 643 had an occluded intracranial artery on admission CTA. Reasons for exclusion for the present study were: no follow-up vascular imaging (n = 289), no
admission body temperature recorded (n = 30), or intra-arterial treatment (n = 46). We included 278 patients, with 288 occluded intracranial arteries. Patient characteristics are presented in Table 1.

Location of the most proximal part of the intracranial occlusion was middle cerebral artery in 215 (75%) arteries, posterior cerebral artery in 30 (10%), the intracranial part of the internal carotid artery in 18 (6%), anterior cerebral artery in 10 (4%), basilar artery in 8 (3%), and another artery in 7 (2%) patients. Ten patients had more than one occluded intracranial arteries.

Patients without follow-up imaging were older than patients with follow-up imaging (68 versus 65, P = 0.01), had higher NIHSS scores on admission (13 versus 11, P = 0.01), and had worse outcomes (median mRS 3 versus 2, P < 0.001).

Follow-up imaging was performed at a median of 3 days (IQR 2 days) after admission. Follow-up imaging was CTA (95%) or MR angiography (5%). Recanalization occurred in 229 (80%) of occluded arteries. Partial or complete recanalization was associated with a better outcome compared to no recanalization (median mRS 2 (IQR 3) versus 3 (IQR 2), respectively; P = 0.01).

Body temperature on admission was not associated with recanalization (OR per 0.1°C, 0.98; 95%CI, 0.93–1.03; P = 0.39; adjusted OR (aOR) per 0.1°C, 0.99; 95%CI, 0.94–1.05; P = 0.70) (Table 2, Fig 1), nor with poor outcome (OR per 0.1°C, 0.97; 95%CI, 0.93–1.01; P = 0.09).

Because follow-up imaging was missing in a substantial proportion of patients who were otherwise eligible for our study, we performed post-hoc analyses that modelled several scenarios in these patients. In these post-hoc analyses, we included all patients with a visible intracranial arterial occlusion on admission CTA, with or without follow up imaging. Patients who received intra-arterial treatment were excluded. In a best case scenario assuming that all patients without follow-up imaging had recanalization, body temperature on admission was not associated with recanalization (aOR per 0.1°C, 0.99; 95%CI, 0.95–1.04; P = 0.67). The same

Table 1. Patient characteristics.

| Baseline characteristics n = 278 |
|---------------------------------|
| **Body temperature on admission (°C)** | 36.7 (0.6) |
| **Age (years)** | 66 (14) |
| **Female sex** | 122 (44) |
| **NIHSS score on admission** | 11 (7) |
| **Previous stroke** | 52 (19) |
| **Hypertension** | 143 (51) |
| **Stroke etiology (TOAST)** | |
| Large-artery atherosclerosis | 118 (42) |
| Cardioembolism | 69 (25) |
| Small vessel disease | 0 (0) |
| Other | 20 (7) |
| Unknown | 71 (26) |
| Current smoking | 90 (32) |
| Diabetes mellitus | 28 (10) |
| Treatment with alteplase | 187 (67) |

Data are n (%), median (range), median (interquartile range (IQR)) or mean (standard deviation (SD)) where appropriate. NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment classification

doi:10.1371/journal.pone.0140777.t001
was found in a worst case scenario assuming that none of the patients without follow-up imaging had recanalization (aOR per 0.1°C, 1.01; 95%CI, 0.98–1.04; P = 0.50).

Results stratified by time of the second (follow-up) CT angiography are shown in S3 Table.

Subgroup analyses

Characteristics of patients in subgroups are presented in S1 and S2 Tables. Treatment with iv alteplase was related to recanalization (aOR, 2.44; 95% CI, 1.33–4.28; P = 0.004).

There was neither difference in the relation between body temperature and recanalization between patients treated or not treated with alteplase, nor between patients with large-artery atherosclerosis and patients with cardioembolic stroke (Table 2).

Discussion

Our findings suggest that in patients with acute ischaemic stroke, there is no relation between body temperature on admission and recanalization of an occluded intracranial artery three days later, irrespective of treatment with alteplase.

Most reports on the relation between body temperature and clot lysis concern in vitro studies. These have shown a reduced rate of fibrinolysis by alteplase at lower temperatures [3]. However, in vitro studies may not adequately reflect the in vivo setting of an acute arterial occlusion. Data from animal and human studies are limited. Some clinical studies found an association between higher admission body temperatures and a favourable outcome after

Table 2. Results of unadjusted and adjusted logistic regression on the relation between body temperature and recanalization.

|                          | Unadjusted | Adjusted for age, NIHSS, and treatment with alteplase |
|--------------------------|------------|-------------------------------------------------------|
|                          | OR 95%CI   | p           | OR 95%CI   | p           |
| Overall analysis (n = 278)| 0.98 0.93–1.03 0.39 | | 0.99 0.94–1.05 0.70 | NA |
| Subgroup analyses        |            |            |            |            |
| Treatment with alteplase (n = 187) | 1.02 0.94–1.11 0.66 | | 1.03 0.93–1.13 0.60 | |
| No treatment with alteplase (n = 91) | 0.96 0.90–1.04 0.32 | | 0.97 0.90–1.04 0.33 | 0.20 |
| Large artery atherosclerosis (n = 118) | 0.94 0.87–1.01 0.10 | | 0.95 0.87–1.03 0.22 | |
| Cardio-embolic (n = 69) | 1.01 0.90–1.13 0.91 | | 1.02 0.88–1.19 0.76 | 0.42 |

NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; CI, confidence interval; NA, not applicable

doi:10.1371/journal.pone.0140777.t002

Fig 1. Odds ratios for the relation between body temperature on admission and recanalization.

doi:10.1371/journal.pone.0140777.g001
thrombolysis with alteplase [9, 10], but others did not [11]. No studies have investigated whether this was related to higher recanalization rates.

We did not find a relation between body temperature on admission and recanalization or functional outcome. Other studies have suggested that increased body temperatures in the first few days, rather than on admission, are related to poor outcome [12, 13].

This study has limitations. Body temperature was assessed at admission and recanalization at three (± 2) days. Recanalization occurring after several hours may be of little or no benefit to ischemic tissue, and clinical consequences of delayed recanalization are therefore limited [1]. Previous studies suggest that body temperatures during the first three days may also have affected recanalization rates [14, 15]. However, in this study recanalization was strongly related to alteplase treatment within 4.5 hours, suggesting that most recanalization occurs in the first hours after stroke, and recanalization was associated with improved clinical outcome. The generalizability of our findings is hampered because in numerous patients missed follow-up imaging, but this is unlikely to have a major effect on the findings in this explanatory rather than prognostic study. We did not have data on the occurrence of infections in our population. The inter- or intra-observer variability in the measurement of recanalization was also not determined. Finally, the vast majority of our study population had normal body temperatures. Due to the limited variability in body temperatures, we could not assess associations between recanalization and body temperatures below 36.0°C or above 37.5°C.

Supporting Information

S1 Table. Baseline characteristics of patients treated and not treated with intravenous alteplase.

(SDC)

S2 Table. Baseline characteristics of patients large-artery atherosclerosis and cardioembolism etiology of stroke.

(SDC)

S3 Table. Results of unadjusted and adjusted logistic regression on the relation between body temperature and recanalization, stratified by time of the second CT angiography.

(SDC)

Acknowledgments

The Dutch acute stroke trial (DUST) investigators are: Majoie CB, Roos YB, Academic Medical Center, Amsterdam, The Netherlands; Duijm LE, Keizer K, Catharina Hospital, Eindhoven, The Netherlands; van der Lught A, Dippel DW, Erasmus Medical Center, Rotterdam, The Netherlands; Droogh—de Greve KE, Bienfait HP, Gelre Hospitals, Apeldoorn, The Netherlands; van Walderveen MA, Wermer MJ, Leiden University Medical Center, Leiden, The Netherlands; Lycklama à Nijeholt GJ, Boiten J, Medical Center Haaglanden, The Hague, The Netherlands; van Duyndam D, Kwa VI, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands; Meijer FJ, van Dijk EJ, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Kesselring FO, Hofmeijer J, Rijnstate Hospital, Arnhem, The Netherlands; van Rooij WJ, de Kort PL, St. Elisabeth Hospital, Tilburg, The Netherlands; Pleiter CC, Bakker SL, St. Franciscus Hospital, Rotterdam, The Netherlands; Bot J, Visser MC, VU Medical Center, Amsterdam, The Netherlands; Velthuis BK*, van der Schaaf IC, Dankbaar JW, Mali WP, van Seeters T, Horsch AD, Niesten JM, Biessels GJ, Kappelle LJ, Luitse MJ, van der Graaf Y, University Medical Center Utrecht, Utrecht, The Netherlands.
Author Contributions

Conceived and designed the experiments: MG HBvdW GJB BV. Performed the experiments: MG ADH. Analyzed the data: MG HBvdW GJB BV LJK. Wrote the paper: MG ADH LJK HBvdW GJB BV.

References

1. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: A meta-analysis. Stroke. 2007; 38:967–73. PMID: 17272772
2. Yenari MA, Hemmen TM. Therapeutic hypothermia for brain ischemia: Where have we come and where do we go? Stroke. 2010; 41:S72–4. doi: 10.1161/STROKEAHA.110.599371 PMID: 20876510
3. van der Worp HB, Macleod MR, Kollmar R, European Stroke Research Network for Hypothermia (Euro-HYP). Therapeutic hypothermia for acute ischemic stroke. Ready to start large randomized trials? J Cereb Blood Flow Metab. 2010; 30:1079–93. doi: 10.1038/jcbfm.2010.44 PMID: 20335454
4. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the american heart Association/american stroke association. Stroke. 2013; 44:870–947. doi: 10.1161/STR.0b013e318284056a PMID: 23370205
5. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008; 25:457–507. doi: 10.1159/000131083 PMID: 18477843
6. Lyden PD, Hemmen TM, Grotta J, Rapp K, Raman R. Endovascular therapeutic hypothermia for acute ischemic stroke: ICTuS 2/3 protocol. Int J Stroke. 2014; 9:117–25. doi: 10.1111/ijis.12151 PMID: 24206528
7. van der Worp HB, Macleod MR, Bath PM, Demotes J, Durand-Zaleski I, Gebhardt B, et al. EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke. Int J Stroke. 2014; 9:642–5. doi: 10.1111/ijis.12294 PMID: 24828363
8. van Seetens T, Biessels GJ, van der Schaaf IC, Dankbaar JW, Horsch AD, Luitse MJ, et al. Prediction of outcome in patients with suspected acute ischaemic stroke with CT perfusion and CT angiography: The dutch acute stroke trial (DUST) study protocol. BMC Neurol. 2014; 14:37.2377-14-37.
9. de Ridder I, den Hertog H, van Gemert M, Dippel D, van der Worp B, PAIS investigators. Increased benefit of alteplase in patients with ischemic stroke and a high body temperature. Cerebrovasc Dis. 2013; 35:60–3.
10. Kvistad CE, Thomassen L, Waje-Andreassen U, Logallo N, Naess H. Body temperature and major neurological improvement in IPA-treated stroke patients. Acta Neurol Scand. 2014; 129:325–9. doi: 10.1111/ane.12184 PMID: 24111500
11. Kim SH, Saver JL. Initial body temperature in ischemic stroke: Nonpotentiation of tissue-type plasminogen activator benefit and inverse association with severity. Stroke. 2015; 46:136–6. doi: 10.1161/STROKEAHA.114.006107 PMID: 25424482
12. Saini M, Saqur M, Kamruzzaman A, Lees KR, Shuaib A, VISTA Investigators. Effect of hyperthermia on prognosis after acute ischemic stroke. Stroke. 2009; 40:3051–9. doi: 10.1161/STROKEAHA.109.556134 PMID: 19644066
13. den Hertog HM, van der Worp HB, van Gemert HM, Algra A, Kappelle LJ, van Ginj J, et al. An early rise in body temperature is related to unfavorable outcome after stroke: Data from the PAIS study. J Neurol. 2011; 258:302–7. doi: 10.1007/s00415-010-5756-4 PMID: 20878419
14. Emron L, Schrooten M, Thijs V. Body temperature and outcome after stroke thrombolysis. Acta Neurol Scand. 2006 Jul; 114(1):23–8. PMID: 16774623
15. Millan M, Grau L, Castellanos M, Rodriguez-Yanez M, Arenillas JF, Nombela F, et al. Body temperature and response to thrombolytic therapy in acute ischaemic stroke. Eur J Neurol. 2008 Dec; 15(12):1384–9 doi: 10.1111/j.1468-1331.2008.02321.x PMID: 19049558